News
Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...
6h
The Star on MSNKenya among countries to receive drug given twice-yearly to prevent HIVThe Global Fund has announced that it signed an access agreement with Gilead Sciences to procure lenacapavir, a twice-a-year injection that has a 99 per cent success rate in preventing HIV ...
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
Gilada, the only Indian serving on the International AIDS Society (IAS) Governing Council, assured the country has the ...
Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...
A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.
If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...
The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...
Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).
Note that some links may require registration or subscription. The Department of Justice said it sent more than 20 subpoenas to doctors and clinics involved with transgender medical procedures on ...
Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...
The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results